ImmunityBio ISPOR data show why NMIBC treatment choices are becoming harder to standardize
Bladder cancer care is shifting from survival alone to treatment trade-offs. ImmunityBio’s NMIBC survey shows why preference now matters.
Why ImmunityBio’s ANKTIVA European launch could reshape BCG-unresponsive bladder cancer care
ImmunityBio expands ANKTIVA into Europe with Accord Healthcare. Discover what this means for bladder cancer care, regulation, and real-world adoption.